HC Wainwright Reiterates Buy Rating for BiomX (NYSEAMERICAN:PHGE)

BiomX (NYSEAMERICAN:PHGE)‘s stock had its “buy” rating reiterated by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $15.00 price target on the stock.

BiomX Stock Performance

PHGE stock opened at $0.5411 on Wednesday. The stock has a fifty day simple moving average of $0.46. BiomX has a twelve month low of $0.34 and a twelve month high of $1.6196. The stock has a market capitalization of $14.36 million, a price-to-earnings ratio of -0.40 and a beta of 1.42.

BiomX Company Profile

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).